The postoperative pain therapeutics market is transforming the global pain management landscape. With the growing emphasis on patient recovery, safety, and opioid alternatives, this episode explores the evolving treatment landscape—from non-opioid medications and local anesthetics to innovative multimodal approaches like ERAS protocols. We also spotlight Hikma Pharmaceuticals' February 2024 launch of COMBOGESIC IV in the U.S.—a new opioid-free IV painkiller combining 1,000 mg acetaminophen and 300 mg ibuprofen. Tune in to understand the shift towards safer, more effective postoperative pain relief.